Influence of metyrapone on plasma concentrations of testosterone and androstenedione in man.
D015065:17-Hydroxycorticosteroids / Q000652:urine; D015068:17-Ketosteroids / Q000097:blood / Q000652:urine; D000224:Addison Disease / Q000097:blood; D000284:Administration, Oral; D000293:Adolescent; D000328:Adult; D000368:Aged; D000731:Androstanes / Q000097:blood*; D001681:Biological Assay; D001835:Body Weight; D003348:Cortisone / Q000494:pharmacology; D003907:Dexamethasone / Q000494:pharmacology; D005260:Female; D006062:Gonadotropins / Q000652:urine; D006801:Humans; D006854:Hydrocortisone / Q000494:pharmacology; D007006:Hypogonadism / Q000097:blood; D007275:Injections, Intravenous; D007713:Klinefelter Syndrome / Q000097:blood; D008297:Male; D008797:Metyrapone / Q000494:pharmacology*; D008875:Middle Aged; D009765:Obesity / Q000097:blood; D011865:Radioisotope Dilution Technique; D013739:Testosterone / Q000037:antagonists & inhibitors / Q000097:blood*; D013997:Time Factors
D015065:17-Hydroxycorticosteroids; D015068:17-Ketosteroids; D000731:Androstanes; D006062:Gonadotropins; D013739:Testosterone; D003907:Dexamethasone; D003348:Cortisone; D006854:Hydrocortisone; D008797:Metyrapone